DK2220047T3 - Quinolinderivater, farmaceutiske sammensætninger omfattende dem og anvendelse deraf - Google Patents
Quinolinderivater, farmaceutiske sammensætninger omfattende dem og anvendelse deraf Download PDFInfo
- Publication number
- DK2220047T3 DK2220047T3 DK08850996.3T DK08850996T DK2220047T3 DK 2220047 T3 DK2220047 T3 DK 2220047T3 DK 08850996 T DK08850996 T DK 08850996T DK 2220047 T3 DK2220047 T3 DK 2220047T3
- Authority
- DK
- Denmark
- Prior art keywords
- pharmaceutically acceptable
- compound
- substituted
- compound according
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (13)
1 λ *-ui»-»r-i/-si/— /-s/t\ C)
hvor n er 0; R1 er hydrogen; R2 er valgt fra mættet eller umættet, forgrenet eller uforgrenet Ci-io alkyl eller C3-12 cycloalkyl, og substitueret eller ikke-substitueret fenyl eller benzyl; R3 er hydrogen; R4 er substitueret eller ikke-substitueret C6-C10 aryl eller C1-C9 heteroaryl hvor heteroatomerne uafhængigt er valgt fra N, O og S; eller substitueret eller ikke-substitueret mono- eller bicyklisk C3-12 cycloalkyl eller C1-C9 heterocyclyl hvor heteroatomerne er uafhængigt valgt fra N, O og S; og farmaceutisk acceptable salte deraf.
2. Forbindelse ifølge krav 1, hvor R2 er valgt fra C1-4 alkyl og C3-4 cycloalkyl.
3. Forbindelse ifølge krav 1, hvor R2 er C1-4 alkyl.
4. Forbindelse ifølge krav 1, hvor R2 er methyl.
5. Forbindelse ifølge et hvilket som helst af kravene 1-4, hvor R4 er substitueret eller ikke-substitueret fenyl. 2
6. Forbindelse ifølge krav 1, hvilken er:
6-(methylcarbamoyl)-4-[(4-methylphenyl)amino]quinolin-3-carboxylsyre, eller et farmaceutisk acceptabelt salt deraf.
7. Forbindelse ifølge krav 1, hvilken er:
4-[(4-methoxyphenyl)amino]-6-(methylcarbamoyl)quinolin-3-carboxylsyre, eller et farmaceutisk acceptabelt salt deraf.
8. Forbindelse ifølge et hvilket som helst af kravene 1-7 eller et farmaceutisk acceptabelt salt deraf til anvendelse i terapi.
9. Farmaceutisk sammensætning omfattende en terapeutisk effektiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1-7, eller et farmaceutisk acceptabelt salt deraf, og mindst en farmaceutisk acceptabel excipiens.
10. Farmaceutisk sammensætning ifølge krav 9, omfattende mindst en yderligere, farmaceutisk aktiv forbindelse.
11. Farmaceutisk sammensætning ifølge krav 10, hvor den yderligere, farmaceutisk aktive forbindelse har en antitumor aktivitet.
12. Forbindelse ifølge et hvilket som helst af kravene 1-7, eller et farmaceutisk acceptabelt salt deraf, til anvendelse i behandlingen af en sygdom valgt fra cancer, diabetiske retinopati, aldersrelateret maculadegeneration, inflammation, slagtilfælde, iskæmisk myocardium, aterosklerose, macular ødem og psoriasis. 3
13. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1-7, eller et farmaceutisk acceptabelt salt deraf, til fremstillingen af et lægemiddel til behandlingen afen sygdom valgt fra cancer, diabetisk retinopati, aldersrelateret maculadegeneration, inflammation, slagtilfælde, iskæmisk myocardium, 5 aterosklerose, macular ødem og psoriasis.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98814707P | 2007-11-15 | 2007-11-15 | |
| EP07120799 | 2007-11-15 | ||
| PCT/EP2008/065596 WO2009063070A2 (en) | 2007-11-15 | 2008-11-14 | Quinoline derivatives and their use as tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2220047T3 true DK2220047T3 (da) | 2015-06-29 |
Family
ID=39295948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08850996.3T DK2220047T3 (da) | 2007-11-15 | 2008-11-14 | Quinolinderivater, farmaceutiske sammensætninger omfattende dem og anvendelse deraf |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8557843B2 (da) |
| EP (1) | EP2220047B1 (da) |
| JP (1) | JP5565841B2 (da) |
| KR (1) | KR101572929B1 (da) |
| CN (1) | CN103476755B (da) |
| AU (1) | AU2008322858B2 (da) |
| BR (1) | BRPI0820210A2 (da) |
| CA (1) | CA2705820C (da) |
| DK (1) | DK2220047T3 (da) |
| EA (1) | EA018798B1 (da) |
| ES (1) | ES2540219T3 (da) |
| HR (1) | HRP20150583T1 (da) |
| HU (1) | HUE025421T2 (da) |
| IL (1) | IL205308A (da) |
| MX (1) | MX2010005039A (da) |
| NZ (1) | NZ585090A (da) |
| PL (1) | PL2220047T3 (da) |
| PT (1) | PT2220047E (da) |
| RS (1) | RS54061B1 (da) |
| SI (1) | SI2220047T1 (da) |
| WO (1) | WO2009063070A2 (da) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102933081B (zh) | 2010-04-02 | 2016-04-13 | 赛诺米克斯公司 | 甜味改良剂 |
| SG10201606309WA (en) | 2011-08-12 | 2016-09-29 | Senomyx Inc | Sweet flavor modifier |
| WO2013103317A1 (en) * | 2012-01-05 | 2013-07-11 | Clanotech Ab | Quinoline compounds which are anti-angiogenic integrin alpha5 betal inhibitors for use in the treatment of fibrosis or fibrosis-related diseases |
| AU2015343463A1 (en) | 2014-11-07 | 2017-06-15 | Senomyx, Inc. | Substituted 4-amino-5-(cyclohexyloxy)quinoline-3-carboxylic acids as sweet flavor modifiers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5650415A (en) * | 1995-06-07 | 1997-07-22 | Sugen, Inc. | Quinoline compounds |
| GB9910577D0 (en) * | 1999-05-08 | 1999-07-07 | Zeneca Ltd | Chemical compounds |
| GB0324270D0 (en) * | 2003-10-16 | 2003-11-19 | Univ Edinburgh | Improved control of ES cell self-renewal and lineage specification, and medium therefor |
| AR059224A1 (es) * | 2006-01-31 | 2008-03-19 | Jerini Ag | Compuestos para la inhibicion de integrinas y uso de estas |
| WO2007139496A1 (en) * | 2006-05-30 | 2007-12-06 | Clanotech Ab | Quinoline derivatives acting as tyrosine kinase inhibitors |
| WO2008119771A2 (en) | 2007-03-30 | 2008-10-09 | Clanotech Ab | Quinoline-s-carboxylic acid derivatives as tyrosine kinase inhibitors |
-
2008
- 2008-11-14 CA CA2705820A patent/CA2705820C/en active Active
- 2008-11-14 DK DK08850996.3T patent/DK2220047T3/da active
- 2008-11-14 PT PT88509963T patent/PT2220047E/pt unknown
- 2008-11-14 EP EP20080850996 patent/EP2220047B1/en active Active
- 2008-11-14 US US12/742,944 patent/US8557843B2/en active Active
- 2008-11-14 RS RS20150411A patent/RS54061B1/en unknown
- 2008-11-14 PL PL08850996T patent/PL2220047T3/pl unknown
- 2008-11-14 EA EA201000803A patent/EA018798B1/ru not_active IP Right Cessation
- 2008-11-14 CN CN200880116202.5A patent/CN103476755B/zh active Active
- 2008-11-14 NZ NZ585090A patent/NZ585090A/en not_active IP Right Cessation
- 2008-11-14 MX MX2010005039A patent/MX2010005039A/es active IP Right Grant
- 2008-11-14 ES ES08850996.3T patent/ES2540219T3/es active Active
- 2008-11-14 AU AU2008322858A patent/AU2008322858B2/en active Active
- 2008-11-14 BR BRPI0820210A patent/BRPI0820210A2/pt not_active Application Discontinuation
- 2008-11-14 HU HUE08850996A patent/HUE025421T2/en unknown
- 2008-11-14 SI SI200831443T patent/SI2220047T1/sl unknown
- 2008-11-14 JP JP2010533600A patent/JP5565841B2/ja not_active Expired - Fee Related
- 2008-11-14 WO PCT/EP2008/065596 patent/WO2009063070A2/en active Application Filing
- 2008-11-14 KR KR1020107013103A patent/KR101572929B1/ko active IP Right Grant
-
2010
- 2010-04-25 IL IL205308A patent/IL205308A/en active IP Right Grant
-
2013
- 2013-08-30 US US14/014,867 patent/US8957092B2/en active Active
-
2015
- 2015-06-01 HR HRP20150583TT patent/HRP20150583T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0820210A2 (pt) | 2017-05-09 |
| EA018798B1 (ru) | 2013-10-30 |
| MX2010005039A (es) | 2010-07-30 |
| US20140018388A1 (en) | 2014-01-16 |
| KR20100097158A (ko) | 2010-09-02 |
| EA201000803A1 (ru) | 2011-02-28 |
| PL2220047T3 (pl) | 2015-08-31 |
| AU2008322858B2 (en) | 2013-05-02 |
| SI2220047T1 (sl) | 2015-07-31 |
| US8557843B2 (en) | 2013-10-15 |
| US20110053976A1 (en) | 2011-03-03 |
| KR101572929B1 (ko) | 2015-11-30 |
| RS54061B1 (en) | 2015-10-30 |
| JP5565841B2 (ja) | 2014-08-06 |
| WO2009063070A2 (en) | 2009-05-22 |
| ES2540219T3 (es) | 2015-07-09 |
| HRP20150583T1 (hr) | 2015-07-31 |
| EP2220047B1 (en) | 2015-05-06 |
| CA2705820A1 (en) | 2009-05-22 |
| NZ585090A (en) | 2011-09-30 |
| PT2220047E (pt) | 2015-07-30 |
| EP2220047A2 (en) | 2010-08-25 |
| JP2011503151A (ja) | 2011-01-27 |
| CN103476755B (zh) | 2015-08-26 |
| IL205308A (en) | 2015-03-31 |
| US8957092B2 (en) | 2015-02-17 |
| AU2008322858A1 (en) | 2009-05-22 |
| CN103476755A (zh) | 2013-12-25 |
| WO2009063070A3 (en) | 2009-07-23 |
| CA2705820C (en) | 2016-06-07 |
| HUE025421T2 (en) | 2016-02-29 |
| IL205308A0 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010133672A1 (en) | Derivatives of quinoline-3-carboxylic acid and their medical use | |
| KR100896973B1 (ko) | 대식세포 이동저해인자의 저해제 및 전기 저해제를규명하는 방법 | |
| CA2832763C (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
| TW201629057A (zh) | 新穎化合物αｖβ整聯蛋白拮抗劑 | |
| TW201629056A (zh) | 新穎化合物αｖβ整聯蛋白拮抗劑 | |
| WO2012143415A1 (en) | Tetrahydroquinoline derivatives useful as bromodomain inhibitors | |
| US8957092B2 (en) | Quinoline derivatives and their use as tyrosine kinase inhibitors | |
| CN111108083B (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 | |
| WO2007139496A1 (en) | Quinoline derivatives acting as tyrosine kinase inhibitors | |
| US20120065199A1 (en) | Substituted quinolines for use as vegf inhibitors | |
| AU2013203571A1 (en) | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl} -4-(dimethylamino)-2-butenamide and crystalline forms thereof | |
| RU2562773C2 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения | |
| UA102082C2 (uk) | Похідні хіноліну та їх застосування як інгібіторів тирозинкінази | |
| KR20090005407A (ko) | Ｍｉｆ 활성을 조절하는 시약을 검출하는 방법 |